AMEDEO HIV Infection
2010-12-20
________________ ** New articles ** _________________
1. ABBATE I, Vlassi C, Rozera G, Bruselles A, et al.
Detection of quasispecies variants predicted to use CXCR4 by ultra-deep
pyrosequencing during early HIV infection.
AIDS. 2010.
ABSTRACT available
2. REYNOLDS SJ, Makumbi F, Nakigozi G, Kagaayi J, et al.
HIV-1 transmission among HIV-1 discordant couples before and after the
introduction of antiretroviral therapy in Rakai, Uganda.
AIDS. 2010.
ABSTRACT available
3. KARLSSON I, Malleret B, Brochard P, Delache B, et al.
Suppressive activity of regulatory T cells correlates with high CD4+ T-cell
counts and low T-cell activation during chronic SIV infection.
AIDS. 2010.
ABSTRACT available
4. NATH A, Clements JE.
Eradication of HIV from the brain: reasons for pause.
AIDS. 2010.
ABSTRACT available
5. O'CONNOR RM, Shaffie R, Kang G, Ward HD, et al.
Cryptosporidiosis in patients with HIV/AIDS.
AIDS. 2010.
6. BAKANDA C, Birungi J, Mwesigwa R, Ford N, et al.
Association of aging and survival in a large HIV-infected cohort on
antiretroviral therapy in Uganda.
AIDS. 2010.
ABSTRACT available
7. ACHENBACH CJ, Cole SR, Kitahata MM, Casper C, et al.
Mortality after cancer diagnosis in HIV-infected individuals treated with
antiretroviral therapy.
AIDS. 2010.
ABSTRACT available
8. SCHOUTEN J, Cinque P, Gisslen M, Reiss P, et al.
HIV-1 infection and cognitive impairment in the cART-era: a review.
AIDS. 2010.
ABSTRACT available
9. PETROVSKI S, Fellay J, Shianna KV, Carpenetti N, et al.
Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a
homogeneous African population.
AIDS. 2010.
ABSTRACT available
10. BUNUPURADAH T, Kosalaraksa P, Puthanakit T, Mengthaisong T, et al.
Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in
virologically suppressed children.
AIDS. 2010.
ABSTRACT available
11. HO J, Moir S, Wang W, Posada JG, et al.
Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory
B-cell responses in HIV-infected individuals.
AIDS. 2010.
ABSTRACT available
12. GOODMAN DD, Zhou Y, Margot NA, McColl DJ, et al.
Low level of the K103N HIV-1 above a threshold is associated with virological
failure in treatment-naive individuals undergoing efavirenz-containing therapy.
AIDS. 2010.
ABSTRACT available
13. HAIM-BOUKOBZA S, Morand-Joubert L, Flandre P, Valin N, et al.
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load
below 1 copy/ml.
AIDS. 2010.
ABSTRACT available
14. PADOVAN L, Segat L, Crovella S.
A polymorphism in PRF1 gene is associated with HIV-1 vertical transmission in
Brazilian children.
AIDS. 2010.
ABSTRACT available
15. NELSON M, Stellbrink HJ, Podzamczer D, Banhegyi D, et al.
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with
etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
AIDS. 2010.
ABSTRACT available
16. VAN VEEN MG, Presanis AM, Conti S, Xiridou M, et al.
National estimate of HIV prevalence in the Netherlands: comparison and
applicability of different estimation tools.
AIDS. 2010.
ABSTRACT available
17. KAJASTE-RUDNITSKI A, Galli L, Nozza S, Tambussi G, et al.
Induction of protective antibody response by MF59-adjuvanted 2009 pandemic
A/H1N1v influenza vaccine in HIV-1-infected individuals.
AIDS. 2010.
ABSTRACT available
18. THIRUMURTHY H, Jafri A, Srinivas G, Arumugam V, et al.
Two-year impacts on employment and income among adults receiving antiretroviral
therapy in Tamil Nadu, India: a cohort study.
AIDS. 2010.
ABSTRACT available
19. PAPO JK, Bauni EK, Sanders EJ, Brocklehurst P, et al.
Exploring the condom gap: is supply or demand the limiting factor - condom access
and use in an urban and a rural setting in Kilifi district, Kenya.
AIDS. 2010.
ABSTRACT available
20. SOLIMAN EZ, Lundgren JD, Roediger MP, Duprez DA, et al.
Boosted protease inhibitors and the electrocardiographic measures of QT and PR
durations.
AIDS. 2010.
ABSTRACT available
21. BANERJEE S, McCutchan JA, Ances BM, Deutsch R, et al.
Hypertriglyceridemia in combination antiretroviral-treated HIV-positive
individuals: potential impact on HIV sensory polyneuropathy.
AIDS. 2010.
ABSTRACT available
22. TAN DH, Kaul R, Raboud JM, Walmsley SL, et al.
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding
in HIV-infected adults.
AIDS. 2010.
ABSTRACT available
23. CRANE HM, Grunfeld C, Willig JH, Mugavero MJ, et al.
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating
antiretroviral therapy in clinical care.
AIDS. 2010.
ABSTRACT available
24. CURLIN ME, Cassis-Ghavami F, Magaret AS, Spies GA, et al.
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV
infection: a case-control study.
AIDS. 2010.
ABSTRACT available
25. GARRABOU G, Lopez S, Moren C, Martinez E, et al.
Mitochondrial damage in adipose tissue of untreated HIV-infected patients.
AIDS. 2010.
ABSTRACT available
26. KWARA A, Lartey M, Sagoe KW, Court MH, et al.
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected
patients with CYP2B6 516TT genotype on rifampin-containing antituberculous
therapy.
AIDS. 2010.
ABSTRACT available
27. WYATT RT, Chakrabarti BK, Pancera M, Phogat S, et al.
HIV-1 Env Precursor Cleavage State Affects Recognition by Both Neutralizing and
Non-neutralizing gp41 Antibodies.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
28. HERMANIDES HS, Gras L, Winkel CN, Gerstenbluth I, et al.
The Efficacy of Combination Antiretroviral Therapy in HIV Type 1-Infected
Patients Treated in Curacao Compared with Antillean, Surinam, and Dutch HIV Type
1-Infected Patients Treated in The Netherlands.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
29. FLOR-PARRA F, Perez-Pulido AJ, Pachon J, Perez-Romero P, et al.
The HIV Type 1 Protease L10I Minor Mutation Decreases Replication Capacity and
Confers Resistance to Protease Inhibitors.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
30. PALOMBI L, Nielsen-Saines K, Giuliano M, Marazzi MC, et al.
Easier Said than Done: World Health Organization Recommendations for Prevention
of Mother-to-Child-Transmission of HIV: Areas of Concern.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
31. LIAO CF, Wang SF, Lin YT, Ho D, et al.
Identification of the DC-SIGN-interactive domains on the envelope glycoprotein of
HIV-1 CRF07_BC.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
32. MAESO R, Huarte N, Julien JP, Kunert R, et al.
INTERACTION OF ANTI-HIV-1 ANTIBODY 2F5 WITH PHOSPHOLIPID BILAYERS AND ITS
RELEVANCE FOR THE MECHANISM OF VIRUS NEUTRALIZATION.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
33. RAFIE C, Campa A, Smith S, Huffman F, et al.
Cocaine Reduces Thymic Endocrine Function: Another Mechanism for Accelerated HIV
Disease Progression.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
34. TRIPATHI A, Youman E, Gibson JJ, Duffus W, et al.
The Impact of Retention in Early HIV Medical Care on Viro-immunological
Parameters and Survival: A Statewide Study.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
35. LAISAAR KT, Avi R, Dehovitz J, Uuskula A, et al.
ESTONIA at the threshold of the fourth decade of the AIDS era in Europe.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
36. BROGLY SB, Dimauro S, Vandyke R, Williams PL, et al.
Transplacental nucleoside analogue exposure and mitochondrial parameters in
HIV-uninfected children.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
37. YOUNG JM, Turpin J, Musib R, Sharma OK, et al.
Outcomes of a NIAID Workshop on Understanding HIV Exposed but Seronegative (HESN)
Individuals.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
38. PARRY CM, Kolli M, Myers RE, Cane PA, et al.
Three Residues in HIV-1 Matrix Contribute to Protease Inhibitor Susceptibility
and Replication Capacity.
Antimicrob Agents Chemother. 2010.
ABSTRACT available
39. WANG J, Reuschel EL, Shackelford JM, Jeang L, et al.
HIV-1 Vif promotes the G1-to-S phase cell cycle transition.
Blood. 2010.
ABSTRACT available
40. YAO H, Duan M, Buch S.
Cocaine-mediated induction of platelet-derived growth factor: implication for
increased vascular permeability.
Blood. 2010.
ABSTRACT available
41. ALLERS K, Hutter G, Hofmann J, Loddenkemper C, et al.
Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell
transplantation.
Blood. 2010.
ABSTRACT available
42. RAMAMOORTHY S, Devaraj B, Miyai K, Luo L, et al.
John Cunningham virus T-antigen expression in anal carcinoma.
Cancer. 2010.
ABSTRACT available
43. HURLEY JH, Boura E, Carlson LA, Rozycki B, et al.
Membrane budding.
Cell. 2010;143:875-87.
ABSTRACT available
44. DOLIN R.
Perspectives on the Role of Immunization against Influenza in HIV-Infected
Patients.
Clin Infect Dis. 2011;52:147-9.
45. CRUM-CIANFLONE NF, Eberly LE, Duplessis C, Maguire J, et al.
Immunogenicity of a Monovalent 2009 Influenza A (H1N1) Vaccine in an
Immunocompromised Population: A Prospective Study Comparing HIV-Infected Adults
with HIV-Uninfected Adults.
Clin Infect Dis. 2011;52:138-46.
ABSTRACT available
46. MADHI SA, Maskew M, Koen A, Kuwanda L, et al.
Trivalent inactivated influenza vaccine in african adults infected with human
immunodeficient virus: double blind, randomized clinical trial of efficacy,
immunogenicity, and safety.
Clin Infect Dis. 2011;52:128-37.
ABSTRACT available
47. BICKEL M, von Hentig N, Wieters I, Khaykin P, et al.
Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic
H1N1 Influenza A Vaccine in HIV-1-Infected Patients.
Clin Infect Dis. 2011;52:122-7.
ABSTRACT available
48. MENENDEZ C, Serra-Casas E, Scahill MD, Sanz S, et al.
HIV and Placental Infection Modulate the Appearance of Drug-Resistant Plasmodium
falciparum in Pregnant Women who Receive Intermittent Preventive Treatment.
Clin Infect Dis. 2011;52:41-8.
ABSTRACT available
49. WAGNER TA, Frenkel LM.
Antiretroviral treatment for HIV-infected infants exposed to nevirapine.
JAMA. 2010;304:2589.
50. LUMBIGANON P, Kariminia A, Aurpibul L, Hansudewechakul R, et al.
Survival of HIV-infected children: A cohort study from the Asia-Pacific region.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
51. DE ARAUJO ES, Dahari H, Cotler SJ, Layden TJ, et al.
Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B
polymorphism in HIV/HCV co-infected patients.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
52. PHANUPHAK N, Pattanachaiwit S, Pankam T, Pima W, et al.
Active voluntary counseling and testing with integrated CD4 count service can
enhance early HIV testing and early CD4 count measurement: experiences from the
Thai Red Cross Anonymous Clinic in Bangkok, Thailand.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
53. LESSELLS RJ, Mutevedzi PC, Cooke GS, Newell ML, et al.
Retention in HIV care for individuals not yet eligible for antiretroviral
therapy: rural KwaZulu-Natal, South Africa.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
54. HURT CB, Hightow-Weidman LB, Matthews DD.
Authors' Reply: Age Disparity Between Sex Partners of Men Who Have Sex With Men
Is Only a Marker of HIV Risk.
J Acquir Immune Defic Syndr. 2011;56:e36.
55. POTTERAT JJ, Brewer DD.
Age Disparity Between Sex Partners of Men Who Have Sex With Men Is Only a Marker
of HIV Risk.
J Acquir Immune Defic Syndr. 2011;56:e35.
56. CASTAGNA A, Cossarini F, Spagnuolo V, Gianotti N, et al.
Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients With
Lamivudine-Resistant HIV-1 Infection.
J Acquir Immune Defic Syndr. 2011;56:e34-5.
57. ALDHAMEN YA, Appledorn DM, Seregin SS, Liu CJ, et al.
Expression of the SLAM Family of Receptors Adapter EAT-2 as a Novel Strategy for
Enhancing Beneficial Immune Responses to Vaccine Antigens.
J Immunol. 2010.
ABSTRACT available
58. GRENNINGLOH R, Tai TS, Frahm N, Hongo TC, et al.
Ets-1 Maintains IL-7 Receptor Expression in Peripheral T Cells.
J Immunol. 2010.
ABSTRACT available
59. NIGAM P, Kwa S, Velu V, Amara RR, et al.
Loss of IL-17-Producing CD8 T Cells during Late Chronic Stage of Pathogenic SIV
Infection.
J Immunol. 2010.
ABSTRACT available
60. BAETEN JM, Lingappa J, Beck I, Frenkel LM, et al.
Herpes Simplex Virus Type 2 Suppressive Therapy with Acyclovir or Valacyclovir
Does Not Select for Specific HIV-1 Resistance in HIV-1/HSV-2 Dually Infected
Persons.
J Infect Dis. 2011;203:117-21.
ABSTRACT available
61. GOLDSTONE S, Palefsky JM, Giuliano AR, Moreira ED Jr, et al.
Prevalence of and Risk Factors for Human Papillomavirus (HPV) Infection Among
HIV-Seronegative Men Who Have Sex With Men.
J Infect Dis. 2011;203:66-74.
ABSTRACT available
62. NYITRAY AG, Carvalho da Silva RJ, Baggio ML, Lu B, et al.
Age-Specific Prevalence of and Risk Factors for Anal Human Papillomavirus (HPV)
among Men Who Have Sex with Women and Men Who Have Sex with Men: The HPV in Men
(HIM) Study.
J Infect Dis. 2011;203:49-57.
ABSTRACT available
63. CHEN DY, Balamurugan A, Ng HL, Yang OO, et al.
Antiviral Activity of HIV-1 Gag-Specific Cytotoxic T Lymphocyte Targeting Is Not
Necessarily Intrinsically Superior To Envelope Targeting.
J Virol. 2010.
ABSTRACT available
64. CANO J, Kalpana GV.
Inhibition of early stages of HIV-1 assembly by INI1/hSNF5 transdominant negative
mutant S6.
J Virol. 2010.
ABSTRACT available
65. MAAMARY J, Array F, Gao Q, Garcia-Sastre A, et al.
Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein
induces a potent gag specific immune response in mice.
J Virol. 2010.
ABSTRACT available
66. MUSICH T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, et al.
A conserved determinant in the V1 loop of HIV-1 that modulates the V3 loop to
prime low CD4 use and macrophage infection.
J Virol. 2010.
ABSTRACT available
67. DUSSUPT V, Sette P, Bello NF, Javid MP, et al.
Basic residues in the Nucleocapsid domain of Gag are critical for late events of
HIV-1 budding.
J Virol. 2010.
ABSTRACT available
68. WILLIAMS LD, Bansal A, Sabbaj S, Heath SL, et al.
Interleukin-21-producing HIV-1-specific CD8 T cells are Preferentially Seen in
Elite Controllers.
J Virol. 2010.
ABSTRACT available
69. SOARES RS, Tendeiro R, Foxall RB, Baptista AP, et al.
Cell-associated viral burden provides evidence of ongoing viral replication in
aviremic HIV-2 infected patients.
J Virol. 2010.
ABSTRACT available
70. KILLIAN MS, Johnson C, Teque F, Fujimura S, et al.
Natural Suppression of HIV-1 Replication Is Mediated By Transitional Memory CD8+
T Cells.
J Virol. 2010.
ABSTRACT available
71. LACHENAL G, Marx P, Schneider W, Drucker E, et al.
Simian viruses and emerging diseases in human beings.
Lancet. 2010;376:1901-2.
72. PARFITT T.
Crime and unjust punishment in Russia.
Lancet. 2010;376:1815-6.
73. USHER AD.
Defrauding of the global fund gives Sweden cold feet.
Lancet. 2010;376:1631.
74. MOORE DP, Klugman KP, Madhi SA.
Role of Streptococcus pneumoniae in hospitalization for acute community-acquired
pneumonia associated with culture-confirmed Mycobacterium tuberculosis in
children: a pneumococcal conjugate vaccine probe study.
Pediatr Infect Dis J. 2010;29:1099-04.
ABSTRACT available
75. ZAMPOLI M, Morrow B, Hsiao NY, Whitelaw A, et al.
Prevalence and Outcome of Cytomegalovirus-associated Pneumonia in Relation to
Human Immunodeficiency Virus Infection.
Pediatr Infect Dis J. 2010.
ABSTRACT available
76. FLAGG EW, Weinstock H.
Incidence of Neonatal Herpes Simplex Virus Infections in the United States, 2006.
Pediatrics. 2010.
ABSTRACT available
77. MCMICHAEL AJ, Jones EY.
Genetics. First-class control of HIV-1.
Science. 2010;330:1488-90.
78. ARIAS MA, Loxley A, Eatmon C, Van Roey G, et al.
Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and
humoral immune responses to HIV-gp140 antigen.
Vaccine. 2010.
ABSTRACT available
79. DIERYNCK I, De Meyer S, Lathouwers E, Vanden Abeele C, et al.
In vitro susceptibility and virological outcome to darunavir and lopinavir are
independent of HIV type-1 subtype in treatment-naive patients.
Antivir Ther. 2010;15:1161-9.
ABSTRACT available
80. RANDELL PA, Jackson AG, Boffito M, Back DJ, et al.
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body
insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Antivir Ther. 2010;15:1125-32.
ABSTRACT available
81. MUSIIME V, Kendall L, Bakeera-Kitaka S, Snowden WB, et al.
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and
abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Antivir Ther. 2010;15:1115-1124.
ABSTRACT available
82. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected
individuals: the D:A:D Cohort Study.
Antivir Ther. 2010;15:1077-1086.
ABSTRACT available
_____________________ ** End ** ______________________
We have screened the following journals for you:
AIDS
AIDS Clin Care
AIDS Read
AIDS Res Hum Retroviruses
Am J Epidemiol
Am J Hematol
Am J Med
Ann Intern Med
Ann Neurol
Antimicrob Agents Chemother
Antivir Ther
Arch Dermatol
Arch Dis Child
Arch Intern Med
Arch Neurol
Blood
BMJ
Br J Dermatol
Br J Haematol
Cancer
Cell
Clin Infect Dis
Dermatology
Drugs
HIV Med
Immunology
Int J Cancer
Int J Dermatol
J Acquir Immune Defic Syndr
J Am Acad Dermatol
J Clin Immunol
J Clin Invest
J Clin Oncol
J Immunol
J Infect Dis
J Med Virol
J Pediatr
J Virol
JAMA
Lancet
MMWR
N Engl J Med
Nat Med
Nature
Neurology
Pediatr Infect Dis J
Pediatrics
Proc Natl Acad Sci U S A
Scand J Infect Dis
Science
Vaccine
Virology
_________________________________________________________
No comments:
Post a Comment